J&J Acquires Alios BioPharma | Chemical & Engineering News
Volume 92 Issue 40 | p. 21 | Concentrates
Issue Date: October 6, 2014

J&J Acquires Alios BioPharma

Department: Business
Keywords: pharma, biotech, RSV, HCV, M&A

In a bid to strengthen its virology portfolio, Johnson & Johnson will pay $1.75 billion in cash for South San Francisco-based Alios BioPharma. With the purchase, J&J gains AL-8176, a small molecule in Phase II studies as a treatment for respiratory syncytial virus (RSV), a common infection that can require hospitalization for infants. J&J says AL-8176 complements its own efforts in RSV. But stock analysts note that the big pharma firm also gains two early-stage hepatitis C virus (HCV) compounds. J&J already markets the HCV treatment Olysio, which in the first half of 2014 brought in nearly $1.2 billion in sales.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment